Dementia and Alzheimer Disease

Leah Croll, MD, a neurology resident on the front lines of the COVID-19 pandemic, shares details from her study on the psychosocial impact on physicians and her first-hand experience.

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic highlighted the most pressing needs within the Alzheimer disease community.

The director of the Sagol Center for Hyperbaric Medicine and Research at Yitzhak Shamir Medical Center offers takeaways on hyperbaric oxygen therapy.

Researchers from Mayo Clinic reported characteristics of 55 patients with a newly defined form of Alzheimer disease with unusual or atypical symptoms.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 4, 2020.

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic detailed the state of Alzheimer disease and what research particularly grabbed his attention at AAIC 2020.

In part 2 of this interview, Marwan Sabbagh, MD, provides insight on what he feels is the most promising field of research in Alzheimer disease right now.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 28, 2020.

With a positive track record in ALS, the investigational agent now sets its sights on the Alzheimer disease pipeline.

The director of the Sagol Center for Hyperbaric Medicine and Research at Yitzhak Shamir Medical Center discussed how hyperbaric oxygen therapy is being used to attempt to improve the damage from neurodegeneration.

Howard Fillit, MD, founding executive director and chief science officer of the Alzheimer's Drug Discovery Foundation and clinical professor of geriatric medicine and palliative care, medicine, and neuroscience at Mount Sinai School of Medicine, detailed the role telemedicine plays in treating Alzheimer disease.

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic discussed how Alzheimer disease research may change if aducanumab becomes approved.

The authors noted that taken together, the findings suggest that either hearing impairment may affect brain atrophy and neuropathologic burden or that underlying pathologies may impair functional hearing abilities, even prior to dementia onset.

The director emeritus of the Lou Ruvo Center for Brain Health at Cleveland Clinic and vice chair of the Department of Brain Health at the University of Nevada-Las Vegas discussed the role repurposed agents play in Alzheimer disease development.

Researchers noted that further examinations are needed of the genetic heterogeneity depression syndromes to test for causal relationships between distinct subtypes of depression and Alzheimer disease.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 21, 2020.

Marwan Sabbagh, MD, director of the Lou Ruvo Center for Brain Health and a neurologist at Cleveland Clinic, detailed why aducanumab’s upcoming FDA decision bears immense weight for patients with Alzheimer disease and future clinical studies.

The head of the Non-Invasive Brain Stimulation Lab at the Santa Lucia Foundation spoke to the challenges in Alzheimer research, biomarkers, and the next steps for rotigotine in this population.

Researchers noted that the development of a simple scale focused on abnormalities in dementia with Lewy bodies may help to further incorporate the EEG in clinical decision-making.

For both surgical and nonsurgical patients, delirium may play a role as an independent risk factor for long-term cognitive decline, implying that the reduction of the former may improve the latter.

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic discussed the potential of aducanumab and the amyloid theory in patients with Alzheimer disease.

The head of the Non-Invasive Brain Stimulation Lab at the Santa Lucia Foundation discussed the phase 2 findings and offered takeaways on rotigotine’s possible place in Alzheimer treatment.

Neurology News Network for the week ending August 15, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 14, 2020.

Recent news that the FDA has granted the fastest possible review for Biogen’s Alzheimer disease treatment aducanumab may be indicative of the agency’s increasing confidence in the drug.